Inhibitors of c-Jun N-terminal kinases: an update

Pierre Koch; Matthias Gehringer; Stefan A Laufer

doi:10.1021/jm501212r

Inhibitors of c-Jun N-terminal kinases: an update

J Med Chem. 2015 Jan 8;58(1):72-95. doi: 10.1021/jm501212r. Epub 2014 Dec 8.

Authors

Pierre Koch¹, Matthias Gehringer, Stefan A Laufer

Affiliation

¹ Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen , Auf der Morgenstelle 8, 72076 Tübingen, Germany.

PMID: 25415535
DOI: 10.1021/jm501212r

Abstract

The c-Jun N-terminal kinases (JNKs) are serine/threonine kinases implicated in the pathogenesis of various diseases. Recent advances in the development of novel inhibitors of JNKs will be reviewed. Significant progress in the design of JNK inhibitors displaying selectivity versus other kinases has been achieved within the past 4 years. However, the development of isoform selective JNK inhibitors is still an open task.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Central Nervous System Diseases / drug therapy
Humans
Inflammation / drug therapy
Isoenzymes / antagonists & inhibitors
Isoenzymes / chemistry
Isoenzymes / metabolism
JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
JNK Mitogen-Activated Protein Kinases / chemistry
JNK Mitogen-Activated Protein Kinases / metabolism
Models, Molecular
Molecular Structure
Neoplasms / drug therapy
Protein Binding
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / metabolism
Protein Kinase Inhibitors / pharmacology*

Substances

Isoenzymes
Protein Kinase Inhibitors
JNK Mitogen-Activated Protein Kinases